Posts by Sabrina Paganoni, MD, PhD
-
Design and Statistical Innovations in the Healey ALS Platform Trial
Sabrina Paganoni, MD, PhD, Eric A. Macklin, PhD, and colleagues explain the statistical approaches used in the Healey ALS Platform Trial to integrate functional and survival outcomes and account for potential differences in the outcomes of participants within the shared control group.
-
Healey Platform ALS Trial Expected to Expedite U.S. Approval of New Treatments
The Healey Platform ALS Trial, headquartered at Massachusetts General Hospital, launched in July 2020 and is expected to bring new treatments to patients with amyotrophic lateral sclerosis more quickly and at lower cost than randomized, controlled trials of single agents.
-
Sodium Phenylbutyrate–Taurursodiol Slows Functional Decline in Patients with ALS
Treatment with co-formulated, fixed-dose sodium phenylbutyrate–taurursodiol had a modest effect in slowing the decline in total score on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised, a measure of function in daily activities.
-
Mortality from Neurodegenerative Disease Not a Concern in Major League Baseball
All-cause mortality and mortality from neurodegenerative disease are no higher among Major League Baseball than the general population, but playing professional baseball seems to increase mortality from certain cancers.
-
Healey Center Speeds ALS Research for Patient Therapies
The Healey Center at Massachusetts General Hospital is a worldwide leader in ALS research that speeds new therapies to patients.
-
Novel Immunomodulator Safe and Tolerable in Pilot Study for ALS
Building on promising data from preclinical models of ALS, physician-scientists at the Healy Center for ALS at Massachusetts General Hospital have completed the first translational step in developing a new immunomodulatory drug for ALS.
Biography
Sabrina Paganoni is an Assistant Professor at Harvard Medical School. She obtained her MD degree at the University of Milan in Italy and a PhD in Neuroscience at Northwestern University (Chicago, IL). She completed her medical training at Harvard Medical School in Boston (residency at Spaulding Rehabilitation and fellowship at Brigham and Women's Hospital/Massachusetts General Hospital).
Her clinical and research activities relate to her subspecialty interests of neuromuscular medicine and clinical neurophysiology (EMG), with a particular focus on Amyotrophic Lateral Sclerosis (ALS).
In addition to her clinical activity, Dr. Paganoni is actively engaged in clinical research. Her research focuses on ALS therapy development. She is the Principal Investigator of several ALS clinical trials and is interested in using biomarkers to enhance the efficiency of ALS research. She is also passionate about developing innovative assistive technology tools that can improve quality of life for people with disabilities.
Dr. Paganoni holds 3 Board Certifications (Physical Medicine and Rehabilitation, Neuromuscular Medicine, and Electrodiagnostic Medicine)
Dr. Paganoni is a member of the Association of Academic Physiatrists (AAP), American Academy of Neurology (AAN), and American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.